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Abstract Interleukin-1L (IL-1L) is a potent inflammatory
cytokine involved in type 1 diabetes and acts through defined
IL-1L signaling pathways. In the present work we describe
induction of DNA binding activity to signal transducer and
activator of transcription (STAT) in response to IL-1L in clonal
insulin-secreting cells. Moreover, IL-1L activates a short isoform
of STAT-3 that potently stimulates transcription. Immunopre-
cipitation studies reveal an interaction between the activated
STAT-3 and the IL-1 receptor accessory protein indicating an
association between the two signaling pathways. This may be a
novel point of transduction cross talk and an additional
mechanism utilised by IL-1L in the pancreatic L-cell during the
process of type 1 diabetes.
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1. Introduction
Interleukin-1L (IL-1L) is a potent pro-in£ammatory cyto-
kine that signals through the type I interleukin 1 receptor (IL-
1RI) [1,2]. IL-1RI and its essential co-receptor accessory pro-
tein (IL-1RAcP) [3] belong to the immunoglobulin superfam-
ily of receptors and are distinct from other cytokine receptors
[2]. IL-1L is recognised as one of the instrumental factors in
pancreatic islet L-cell destruction during autoimmune pan-
creatitis and type 1 diabetes [4]. IL-1L mediates the intracel-
lular activation through the IL-1RI-associated kinases, death
domain proteins, the sphingomyelin/ceramide cascade, the nu-
clear factor NF-UB, Jun N-terminal kinase and mitogen-acti-
vated protein kinase signaling pathways [1,5^8]. Beta-cell
damage occurs after increased production of nitric oxide
and in£ammatory mediators due to elevated expression of
inducible nitric oxide synthase [9] and cyclooxygenase 2 [10].
This leads to abrogation of glycolytic £ux [11], mitochondrial
respiratory processes [12] and apoptotic cell death [13,14].
The Janus kinase (JAK) and signal transducer and activa-
tors of transcription (STAT) signaling pathway is associated
with cytokines and growth factors that signal through the type
I cytokine receptor superfamily [15^17]. To date, there is little
evidence suggesting cross talk between the IL-1L and JAK/
STAT signaling pathways. There are no obvious JAK or
STAT binding motifs within the IL-1RI or the IL-1RAcP,
and this could indicate that adapter proteins are necessary
to couple these two pathways. In the present study we provide
evidence for the activation of a short isoform of STAT-3 in
response to IL-1L in the pancreatic L-cell model RINm5F.
Furthermore, we ¢nd an interaction of the IL-1RAcP with
STAT-3 that supports a rapid recruitment and activation of
the JAK/STAT pathway after binding of IL-1L to the IL-1RI/
IL-1RAcP complex. Since the susceptibility of the pancreatic
L-cell to IL-1L-mediated damage is in£uenced by its metabolic
status [18,19], we also determined the e¡ect of mimicking in-
creased metabolic activity on this signaling process. We pro-
pose that this novel point of cross talk between two distinct
cytokine signaling pathways may be an additional mechanism
used by IL-1L during the process of pancreatic L-cell destruc-
tion in type 1 diabetes.
2. Materials and methods
2.1. Cell culture and transient transfection
RINm5F cells were routinely cultured as described previously [20].
Cells were exposed to recombinant human IL-1L (Calbiochem, Not-
tingham, UK), glucagon-like peptide-1 (GLP-1) (Bachem, Sa¡ron
Walden, UK), or forskolin and isobutyl methyl xanthine (IBMX)
(Alexis Corp., Nottingham, UK) for the indicated times and concen-
trations in serum-free RPMI 1640 medium. For transfection experi-
ments, interferon-Q-activated sequence (GAS)-chloramphenicol acetyl-
transferase (CAT) containing four copies of the human FcQRI GAS
(5P-AGC TTG AGA TGT ATT TCC CAG AAA AGA-3P), interfer-
on-Q/interleukin-6 response element (IRE)-CAT containing four copies
of the human intercellular adhesion molecule 1 (ICAM-1)-CAT (5P-
AGC TTA GTT TCC GGG AAA GCA C-3P), and L-casein-CAT
containing four copies of the L-casein STAT binding site (5P-AGC
TTA GAT TTC TAG GAA TTC AAA TCA-3P) were used. STAT
binding sites were cloned into the TK-CAT vector pBLCAT2 [21].
Cells were split 1:3 and 24 h later transfected with 10 Wg supercoiled
plasmid DNA by the DEAE-dextran technique. Cells were serum
starved for 16 h, after which the cells were either stimulated with
IL-1L (50 pg/ml) or left untreated for 12 h and subsequently harvested
for CAT assay as described previously [22].
2.2. Mobility shift assay and supershift
Gel shift assay was performed with short STAT consensus binding
element (underlined) from the interferon response factor 1 (IRF-1)
promoter, top strand 5P-GCC TGA TTT CCC CGA AAT GAC
GGC-3P, c-fos promoter, high a⁄nity SIS inducible element
(m67SIE), top strand 5P-CAT TTC CCG TAA ATC AT-3P and rat
L-casein promoters top strand 5P-GGA CTT CTT GGA ATT AAG
GGA-3P, end-labelled with [Q-32P]ATP (Amersham, Little Chalfont,
UK). Supershift experiments were performed with anti-STAT-1 (C-
136X), -3 (C-20X), -5a (L-20X), -5b (C-17X) (Santa Cruz, CA, USA)
and anti-STAT-1 N-terminal (G16920), anti-STAT-3 N-terminal
(S21320), STAT-2 (S21220), and STAT-6 (S25420) (Transduction
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Labs, Lexington, KY, USA) by pre-incubation of nuclear extracts for
15 min at room temperature, or 30 min on ice before addition of
probe. Nuclear extracts were prepared as described previously [23].
2.3. Immunoprecipitation and Western blots
The cells were lysed and the lysate rocked for 30 min at 4‡C. For
phospho (Y705) STAT-3, the lysate was cleared by adding 30 Wl
protein G-Sepharose (Pharmacia) for 1 h, spun down and the super-
natant incubated overnight at 4‡C with 1 Wg/condition of a rabbit
polyclonal anti-phospho (Y705) STAT-3 antibody (New England Bio-
labs). Goat anti-rabbit IgG (Transduction Labs) was then incubated
for 30 min and the complexes pulled down with protein G-Sepharose
beads after a 30 min rock. Immunoprecipitates were then washed and
loaded on 10% SDS-PAGE system. The blots were probed with either
a mouse anti-IL-1RAcP antibody (Transduction Labs) or STAT-3 N-
terminal-speci¢c antibodies (Transduction Labs) and detected with an
anti-mouse horseradish peroxidase-conjugated secondary antibody ac-
cording to the manufacturer’s instructions with an ECL kit (Amer-
sham). Western blot analysis was performed as described previously
[23].
3. Results and discussion
IL-1L (50 pg/ml) induced DNA binding activity to the GAS
element from the IRF-1 promoter (Fig. 1) which was detect-
able by 5 min. Binding of the STAT factor reached a max-
imum at 15^20 min and returned to basal within 30 min con-
sistent with the kinetics of rapid STAT factor activation. IL-
1L induced STAT DNA binding activity in nuclear extracts of
the clonal insulin-secreting cell line RINm5F at concentra-
tions that are within the exposure range that promotes islet
L-cell damage [9^14,18,19]. Thus, the induction of this single
DNA binding complex was observed over the concentration
range of 0.5^500 pg/ml IL-1L with saturation of binding at
5 pg/ml during a 15 min incubation with the IRF-1 probe
(Fig. 1). Using the IRF-1 probe, we were unable to supershift
the complex with C-terminal antibodies to STAT-1, -2, -3,
-5a, -5b or -6 (Fig. 1, lower panel). We also found that IL-
1L (50 pg/ml) induces binding to the DNA m67SIE STAT
element from the c-fos promoter (Fig. 2), a probe known to
bind STAT-3K and STAT-3L avidly. The single complex bind-
ing to the m67SIE probe was readily supershifted with an
anti-N-terminal STAT-3 antibody (Fig. 2). The STAT
m67SIE complex was not supershifted with C-terminal
STAT-3 antibody nor was there any induction of DNA bind-
ing activity to a L-casein oligonucleotide probe in RINm5F
nuclear extracts implying that STAT-5 is not a target for IL-
1L (data not shown).
Nuclear extracts from 50 pg/ml IL-1L-treated RINm5F cells
were also subjected to Western blot and probed with an anti-
body to the tyrosine phosphorylated form of STAT-3 (anti-
phospho (Y705) STAT-3) and an N-terminal-directed STAT-3
antibody. This revealed that IL-1L induces tyrosine phosphor-
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Fig. 1. IL-1L induces time- and dose-dependent DNA binding activ-
ity on the IRF-1 STAT consensus. IL-1L (50 pg/ml)-induced STAT
DNA binding to the IRF-1 is observed by 5 min, peaks at 15^20
min and returns to basal by 30 min (upper panel). The STAT DNA
binding is observed over the concentration range of 0.5^500 pg/ml
(upper panel). Supershift analyses of IL-1L (50 pg/ml)-induced
STAT DNA binding to the IRF-1 with C-terminal antibodies to
STAT-1, -2, -3, -5a, -5b and -6 are shown in the bottom panel. The
arrows point at the STAT DNA complex.
Fig. 2. IL-1L induces STAT-3 DNA binding activity. An appropri-
ate time (15 min) and dose of IL-1L (50 pg/ml) was selected from
results on the IRF-1 probe, to study the e¡ects of IL-1L on m67SIE
binding activity. IL-1L (50 pg/ml) induced the STAT DNA binding
activity of the m67SIE probe that is known to bind STAT-3 avidly.
The arrow points at the STAT DNA band shift.
Fig. 3. IL-1L causes a time-dependent induction of a STAT-3 immu-
noreactive protein in RINm5F nuclear extracts. RINm5F were pre-
incubated in serum-free medium for 24 h and then exposed to IL-
1L (50 pg/ml) for the times indicated below the lanes. Time-depend-
ent induction of a protein complex (V67 kDa) that cross-reacts
with a phospho (Y705) STAT-3 antibody. Time-dependent induction
of a STAT-3 N-terminal immunoreactive protein that co-migrates
with the tyrosine phosphorylated STAT-3 species at approximately
67 kDa.
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ylation of a single STAT-3 isoform (Fig. 3). This band co-
migrated with and followed an identical induction pattern to a
STAT-3 N-terminal immunoreactive species with an apparent
molecular weight of 67 kDa (Fig. 3). The fact that a C-termi-
nal directed STAT-3 antibody does not supershift the IL-1L-
induced DNA binding activity (anti-STAT-3 epitope 750^769)
(Fig. 1) is consistent with the induction of a short STAT-3
isoform. Tyrosine phosphorylation and nuclear translocation
(Fig. 3) correlated well with the time course for STAT DNA
binding (Fig. 1).
In order to determine whether the observed activation of
STAT DNA binding activity also results in transcriptional
activation of STAT target genes, we performed transient
transfection experiments in RINm5F cells (Fig. 4). IL-1L (50
pg/ml) caused a modest activation of a CAT reporter con-
struct containing four copies of the human FcQRI GAS
(GAS-CAT), which can bind STAT-1, -3 and -5. However,
the activity of a CAT reporter construct containing four cop-
ies of the human ICAM-1 IRE (IRE-CAT), which can bind
STAT-1 but has a greater a⁄nity for STAT-3 [24], was
strongly enhanced by IL-1L treatment. By contrast, no in-
crease in CAT activity could be found in cells transfected
with L-casein-CAT containing four copies of the L-casein
STAT binding site, which can bind STAT-1 and e⁄ciently
binds STAT-5, or with the empty pBLCAT2 vector. Taken
together, these results support the activation of a transcrip-
tionally active STAT-3 or a STAT-3-related molecule after
IL-1L treatment of RINm5F cells.
Since the induction of STAT-3 activation occurs rapidly, we
reasoned that there might be an interaction with the ligand-
receptor complex at a membrane proximal level. In order to
address a possible point of interaction between the IL-1RI
system and the activation of STAT-3, we performed immuno-
precipitation studies with an antibody to the activated form of
STAT-3 and probed with an antibody to the IL-1RAcP. This
co-receptor is known to be essential for the full functioning
capability of the IL-1RI complex [2]. We found that there was
a rapid association of STAT-3 with IL-1RAcP that was max-
imal at 2 min and declined over the next 10 min (Fig. 5).
STAT-3 recruitment to ligand-activated cytokine receptors is
usually mediated through STAT SH2 domain binding to ty-
rosine phosphorylated motifs on the receptor [17] and direct
interaction of STATs with JAK are also known to occur [25].
Our data indicate that a further level of association between
activated STAT-3 and the IL-1RAcP may exist. The associa-
tion could be a consequence of the interaction of other regions
of the STAT-3 with the IL-1RAcP complex.
High IL-1L concentrations, prolonged duration of exposure
and high glucose concentrations exacerbate the deleterious
e¡ects of IL-1L on the L-cell [18,19]. We tested whether the
STAT activation mediated by IL-1L, presented in the current
study, could be modulated by conditions that mimic increased
metabolic activity using agents that increase intracellular cy-
clic adenosine monophosphate (cAMP) concentrations as oc-
curs in normal pancreatic L-cells upon exposure to hormones
that potentiate insulin secretion. GLP-1 (10 nM), an endoge-
nously secreted peptide hormone that increases intracellular
cAMP concentrations and stimulates insulin secretion in
RINm5F [26] cells, caused a reduction in IL-1L (50 pg/ml)-
mediated STAT-3 DNA binding (Fig. 6). Increasing the intra-
cellular cAMP concentration with the adenylyl cyclase activa-
tor, forskolin (10 WM) and cAMP phosphodiesterase inhibitor
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Fig. 5. IL-1L induces the interaction of activated STAT-3 with the
IL-1RAcP. RINm5F cells were treated with IL-1L (50 pg/ml) for
the indicated time and then lysed. Immunoprecipitation was per-
formed on whole cell lysates with an anti-phospho STAT-3 Y705
antibody. Identical immunoprecipitates were then probed with either
an N-terminal directed STAT-3 antibody or an anti-IL-1RAcP
monoclonal antibody on separate gels. IL-1L treatment increases the
association with a peak at 2 min that rapidly declines by 10 min.
Fig. 6. Increasing intracellular cAMP attenuates the IL-1L-inducible
STAT DNA binding. The cells were pre-incubated in serum-free me-
dium and then given a second pre-incubation for 15 min with 10
nM GLP-1 or 10 WM forskolin/50 WM IBMX. IL-1L (50 pg/ml) was
then added in the presence of the compounds and the nuclear ex-
tracts isolated. The nuclear extracts were then incubated with
[Q-32P]ATP end-labelled m67SIE probe and the complexes separated
on 4% PAGE gels and analysed by autoradiography.
Fig. 4. IL-1L induces transcriptional activation from the IRE-CAT.
RINm5F cells were transiently transfected with reporter plasmids
driven by the STAT consensus promoter element indicated below
the axis. After a period of serum starvation, the RINm5F were ex-
posed to IL-1L (50 pg/ml) for 12 h and then assessed for induction
of CAT activity. The IRE-CAT reporter construct was strongly in-
duced whereas a slight induction at the GAS-CAT and no induction
from a control plasmid pBL or LCAS-CAT constructs were ob-
served.
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IBMX (50 WM) had a more pronounced e¡ect. This may
implicate a role for cAMP-dependent protein kinases in mod-
ulating IL-1L-mediated signaling. We do not know whether
the STAT-3 mechanism represents the initiation of an early
protective cellular mechanism or contributes to the cellular
toxicity associated with inappropriate exposure to IL-1L.
Our data indicate that acute elevation of L-cell metabolic ac-
tivity could counteract IL-1L-mediated STAT signaling.
The events after IL-1L binding to its receptor have only
recently begun to be elucidated [1^8]. Activation of the
JAK/STAT pathway is associated with growing numbers of
ligands [15^17]. To date, however, only one study has de-
scribed an interaction of the IL-1L signaling pathway and a
STAT-1-like mechanism [27]. We probed nuclear extracts of
IL-1L-treated RINm5F with antibodies to STAT-1 N-termi-
nus and phospho (Y701) STAT-1 and found that this complex
is not induced in this cell line under the conditions used (data
not shown). The STAT-3 isoform activation pro¢le is some-
what di¡erent from the characterised short STAT-3L isoform.
STAT-3L is a splice variant [22], which is functionally distinct
from the full-length STAT-3K. Thus, STAT-3L has a higher
DNA binding a⁄nity but lacks the C-terminal transactivation
domain that is believed to convey transcriptional activity to
STAT-3K [28]. Indeed, STAT-3L can mediate dominant neg-
ative repression of transcription [22] or transcriptional activa-
tion [29] depending on the system studied. Thus, Sasse et al.
[29] have shown that carboxy-terminal truncated STAT-3 pro-
teins are unable to activate promoters in COS-7 cells, whilst in
hepatoma cells (HepG2) they potently activate promoters and
to the same extent as a full-length STAT-3. This would sug-
gest that di¡erent mechanisms exist in di¡erent cell types to
promote transactivation of STAT-3 that is not always depend-
ent on the presence of the carboxy-terminal transactivation
domain. The transactivation observed in response to IL-1L
in the RINm5F cells implies that the short STAT-3 isoform
described here has transcriptional activity in insulin-producing
cells. Regarding whether the STAT-3 mechanism mediates a
protective or destructive e¡ect, it is of note that IRF-1 is
known to have a crucial role in the initiation of apoptosis
and cellular growth retardation [30]. Furthermore, co-opera-
tive interaction between STAT-3L and c-Jun [31], another IL-
1L-responsive transcription factor that has been linked to
apoptosis [32], has also been established. However, since
STAT-3 activation has been associated with diverse and often
opposing phenomena, such as transformation [33] or apopto-
sis and di¡erentiation [34] depending on the system under
study, the role of this signaling mechanism in the fate of the
L-cell during type 1 diabetes will require further studies.
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